Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 79

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 79
---
 of December 31, 2024 and December 31, 2023

    —

    —

    Common shares, no par value per share; unlimited shares authorized as    of  December 31, 2024 and December 31, 2023; 42,510,708 and 42,176,041    shares issued and outstanding as of December 31, 2024 and December 31, 2023,   respectively

    486,674

    483,350

    Warrants

    10

    —

    Additional paid-in capital

    82,191

    61,813

    Accumulated other comprehensive income

    54

    28

    Accumulated deficit

    (417,798
    )

    (333,109
    )

    TOTAL SHAREHOLDERS’ EQUITY

    151,131

    212,082

    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
     
    $
    176,506

    $
    253,901

The accompanying notes are an integral part of these consolidated financial statements 

102

Repare Therapeutics Inc. 

Consolidated Statements of Operations and Comprehensive Loss 

(In thousands of U.S. dollars, except share and per share data) 

    Year Ended December 31,

    2024

    2023

    Revenue:

    Collaboration agreements
     
    $
    53,477

    $
    51,133

    Operating expenses:

    Research and development, net of tax credits

    115,941

    133,593

    General and administrative

    29,680

    33,764

    Restructuring

    1,379

    —

    Total operating expenses

    147,000

    167,357

    Loss from operations

    (93,523
    )

    (116,224
    )

    Other income (expense), net

    Realized and unrealized loss on foreign exchange

    (2
    )

    (170
    )

    Interest income

    10,391

    13,334

    Other expense, net

    (115
    )

    (119
    )

    Total other income, net

    10,274

    13,045

    Loss before income taxes

    (83,249